Preparation of Low Molecular Weight Chondroitin Sulfates, Screening of a High Anti-Complement Capacity of Low Molecular Weight Chondroitin Sulfate and Its Biological Activity Studies in Attenuating Osteoarthritis

Int J Mol Sci. 2016 Oct 11;17(10):1685. doi: 10.3390/ijms17101685.

Abstract

Chondroitin sulfate (CS) plays important roles in the complement system. However, the CS structure is complicated due to different sources and the number and positions of sulfate groups. The objective of this study was to prepare different low molecular weight chondroitin sulfates (LMWCSs) and to investigate the biological activity in anti-complement capacity. A series of LMWCSs was prepared from different sources and characterized by ultraviolet-visible (UV) spectroscopy, high-performance liquid chromatography (HPLC), size exclusion chromatography-multiangle laser light scattering (SEC-MALLS) and nuclear magnetic resonance (NMR) spectroscopy. Hemolytic, anti-complement 3 deposition capacity and cell viability assays were carried out to investigate the biological activities in vitro. The results showed that LMWCS prepared from shark cartilage with the oxidative degradation method (LMWCS-S-O) had the best anti-complement capacity. LMWCS-S-O could inhibit the alternative pathway of the complement system and protect chondrocytes from cell death. The attenuating effect of LMWCS-S-O on Osteoarthritis (OA) was investigated by destabilization of the medial meniscus (DMM) model in vivo. Functional wind-up, histological and C5b-9 analyses were used to evaluate the treatment effect on the OA model. In vivo results showed that LMWCS-S-O could attenuate OA. LMWCS-S-O with a high content of ΔDi-2,6diS and ΔDi-6S could be used for attenuating OA through regulating the complement system.

Keywords: anti-complement; chondroitin sulfate; depolymerization; osteoarthritis.

MeSH terms

  • Animals
  • Cell Survival / drug effects
  • Chondrocytes / drug effects
  • Chondroitin Sulfates / chemistry*
  • Chondroitin Sulfates / pharmacology*
  • Chondroitin Sulfates / therapeutic use
  • Disease Models, Animal
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Molecular Weight
  • Osteoarthritis* / drug therapy
  • Random Allocation
  • Treatment Outcome

Substances

  • Chondroitin Sulfates